| Cathepsin K | |
|---|---|
| Gene | CTSK |
| UniProt | P43235 |
| PDB | 1ATK, 1NL6, 4XDK |
| Mol. Weight | 24.9 kDa |
| Localization | Lysosomes, bone resorption lacunae |
| Family | Papain family cysteine proteases |
| Diseases | Pycnodysostosis, Alzheimer's Disease, Parkinson's Disease |
Cathepsin K is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cathepsin K is a papain-family cysteine protease predominantly expressed in osteoclasts, where it plays a critical role in bone resorption. It is one of the most potent collagenases known, capable of degrading type I and type II collagen at acidic pH. Beyond its well-established role in bone metabolism, emerging research has implicated Cathepsin K in neurodegenerative diseases, particularly Alzheimer's disease and Parkinson's disease, where it participates in amyloid-beta degradation, lysosomal dysfunction, and neuroinflammation.
Cathepsin K is a 329-amino acid cysteine protease synthesized as a preproenzyme. The mature enzyme consists of:
The crystal structure reveals a classic papain-fold with two distinct domains separated by a active site cleft:[1]
Key structural features include:
Cathepsin K is the major protease responsible for degrading bone matrix collagen during osteoclast-mediated bone resorption:[2]
The enzyme is stored in lysosome-like vesicles within osteoclasts and released into the resorption lacunae, where the acidic environment (pH 4.5-5.5) optimizes its activity.
Cathepsin K has emerged as a significant player in AD pathogenesis:
Cathepsin K can degrade both soluble and fibrillar Aβ, functioning as an alternative to neprilysin and IDE:[3]
In AD brain, cathepsin K localization and activity are altered:[4]
Cathepsin K inhibitors have been explored for AD treatment:
In PD, cathepsin K participates in:
Cathepsin K can cleave α-synuclein, potentially generating aggregation-prone fragments:[5]
Cathepsin K expression in substantia nigra:
Several pharmacological approaches have been investigated:
| Drug | Status | Indication | Notes |
|---|---|---|---|
| Odanacatib | Discontinued | Osteoporosis | Showed promise in AD models |
| Balicatib | Discontinued | Osteoporosis | Did not cross BBB |
| MIV-247 | Preclinical | Multiple | Brain-penetrant analog |
The study of Cathepsin K has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.